An Exploratory, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of JTR-161 in Patients With Acute Ischemic Stroke
Latest Information Update: 27 Oct 2022
At a glance
- Drugs JTR 161 (Primary)
- Indications Ischaemic stroke
- Focus Therapeutic Use
- Acronyms J-REPAIR
- Sponsors Teijin Pharma
Most Recent Events
- 29 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 31 Jul 2021 to 31 May 2022.
- 23 Dec 2020 Planned primary completion date changed from 31 Mar 2021 to 31 Jan 2021.